Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2108 - External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases

Date

11 Sep 2017

Session

Poster display session

Presenters

Gaia Griguolo

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

G. Griguolo1, W. Jacot2, E. Kantelhardt3, M.V. Dieci1, C. Bourgier4, C. Thomssen5, C. Bailleux6, F. Miglietta1, A.L. Braccini7, P.F. Conte1, J. Ferrero8, V. Guarneri1, A. Darlix2

Author affiliations

  • 1 Department Of Surgery, Oncology And Gastroenterology, University of Padova, 35128 - Padova/IT
  • 2 Department Of Medical Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 3 Department Of Gynaecology And Institute Of Medical Epidemiology, Biostatistics And Informatics, Martin Luther University Halle-Wittenberg, 06097 - Halle/DE
  • 4 Department Of Radiation Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 5 Department Of Gynaecology, Martin-Luther University Halle-Wittenberg, 06120 - Halle (Saale)/DE
  • 6 Department Of medical Oncology, Centre Antoine Lacassagne, 6100 - Nice/FR
  • 7 Department Of Medical Oncology And Radiotherapy, Centre Azuréen de Cancérologie, 06250 - Mougins/FR
  • 8 Department Of medical Oncology, Centre Antoine Lacassagne, 06100 - Nice/FR
More

Resources

Abstract 2108

Background

Several prognostic indexes have been developed to estimate survival of breast cancer (BC) patients with brain metastases (BM). The Modified Breast Graded Prognostic Assessment (GPA) has been proposed as refinement of the Breast GPA, based on a single-institution cohort of 1,552 patients. In addition to age, tumor subtype and Karnofsky PS, the modified breast GPA comprises number of BM. The aim of this study is to validate the modified breast-GPA in an external multinational cohort.

Methods

Clinical and biological data of 668 BC patients diagnosed with BM at four European institutions between 1996 and 2016 were reviewed. Patients were classified according to breast GPA and modified breast GPA. OS was calculated from time of BM diagnosis to death or last follow up. Cox proportional models were used to calculate Hazard Ratio and 95% Confidence Intervals (CI). Performances of breast-GPA and modified breast-GPA were compared using Harrell's concordance index.

Results

At last follow-up, 632 patients (94.6%) had died. Median OS was 8.1 months (95% CI 6.9-9.4 months). Median age at BM diagnosis was 56 years (range 24-85). Tumor phenotype distribution was: triple negative (20.1%), hormone receptor (HR)-HER2 + (21.6%), HR+HER2 + (20.4%) and HR+HER2- (33.4%). KPS distribution was: 90-100 (19.6%), 70-80 (49.0%), 60 (12.8%) and ≤50 (18.6%). 355 patients (53.5%) had >3 BM. Number of BM (1,2,3,>3) was significantly associated with OS (p 

Conclusions

Number of BM is a significant prognostic factor in BC patients with BM and modified breast-GPA performs better than breast-GPA in predicting prognosis of these patients.

Clinical trial identification

Legal entity responsible for the study

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.